

# Paulina Antosik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5793597/publications.pdf>

Version: 2024-02-01

23  
papers

260  
citations

1162889

8  
h-index

996849

15  
g-index

23  
all docs

23  
docs citations

23  
times ranked

419  
citing authors

#	ARTICLE	IF	CITATIONS
1	Urinary bladder augmentation with acellular biologic scaffoldâ€”A preclinical study in a large animal model. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2022, 110, 438-449.	1.6	4
2	The Prognostic Role of CDK9 in Bladder Cancer. <i>Cancers</i> , 2022, 14, 1492.	1.7	7
3	Prognostic Significance of SATB1, SMAD3, Ezrin and Î²-Catenin in Patients with Pancreatic Adenocarcinoma. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 306.	1.3	0
4	The development of marine biomaterial derived from decellularized squid mantle for potential application as tissue engineered urinary conduit. <i>Materials Science and Engineering C</i> , 2021, 119, 111579.	3.8	9
5	Expression of the Body-Weight Signaling Players: GDF15, GFRAL and RET and their clinical relevance in Gastric Cancer. <i>Journal of Cancer</i> , 2021, 12, 4698-4709.	1.2	9
6	The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101664.	0.7	9
7	Prognostic Significance of KIF11 and KIF14 Expression in Pancreatic Adenocarcinoma. <i>Cancers</i> , 2021, 13, 3017.	1.7	9
8	Short Term Pre-Operative Oral Corticosteroidsâ€”Tissue Remodeling in Chronic Rhinosinusitis with Nasal Polyps. <i>Journal of Clinical Medicine</i> , 2021, 10, 3346.	1.0	6
9	Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Nonâ€”Small-Cell Lung Cancer Patients. <i>Cancer Control</i> , 2021, 28, 107327482110566.	0.7	8
10	The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2547-2557.	1.2	8
11	Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test. <i>Disease Markers</i> , 2020, 2020, 1-10.	0.6	4
12	The impact of TP53BP1 and MLH1 on metastatic capability in cases of locally advanced prostate cancer and their usefulness in clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 600.e17-600.e26.	0.8	0
13	Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options. <i>Journal of Immunology Research</i> , 2020, 2020, 1-7.	0.9	9
14	Expression of Selected Epithelial-Mesenchymal Transition Transcription Factors in Endometrial Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	5
15	Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. <i>Molecular Biology Reports</i> , 2019, 46, 6629-6645.	1.0	77
16	Expression of zinc finger transcription factors (ZNF143 and ZNF281) in serous borderline ovarian tumors and low-grade ovarian cancers. <i>Journal of Ovarian Research</i> , 2019, 12, 23.	1.3	14
17	HER2, NF-Î²B, and SATB1 Expression Patterns in Gastric Cancer and Their Correlation with Clinical and Pathological Parameters. <i>Disease Markers</i> , 2019, 2019, 1-14.	0.6	10
18	Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma. <i>Pathology and Oncology Research</i> , 2019, 25, 1519-1524.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Cellular and molecular alterations induced by low-dose fisetin in human chronic myeloid leukemia cells. <i>International Journal of Oncology</i> , 2019, 55, 1261-1274.	1.4	4
20	Emerging strategies in BRCA-positive pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1503-1507.	1.2	37
21	Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers. <i>Tumor Biology</i> , 2018, 40, 101042831878480.	0.8	10
22	KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system. <i>Tumor Biology</i> , 2017, 39, 101042831773398.	0.8	9
23	Assessment of BRAF V600E (VE <sup>1</sup> ) protein expression and BRAF gene mutation status in codon 600 in benign and malignant salivary gland neoplasms. <i>Journal of Oral Pathology and Medicine</i> , 2017, 46, 340-345.	1.4	8